Recalcitrant pemphigus vulgaris responding to systemic tacrolimus

Area of Science:

• Immunodermatology
• Autoimmune diseases
• Dermatology

Background:

• Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by antibodies against desmoglein 3, leading to skin and mucous membrane erosions.
• Current treatments include systemic glucocorticosteroids and various immunosuppressants, but optimal therapy remains unclear due to PV's low incidence.
• Systemic tacrolimus has not been previously reported as an adjuvant therapy for PV.

Observation:

• Two patients with severe, treatment-resistant oral pemphigus vulgaris were treated with systemic tacrolimus.
• Tacrolimus was administered as an adjuvant therapy alongside existing treatments.
• The patients tolerated tacrolimus well, with no significant adverse events reported.

Findings:

• Successful clinical improvement was observed in both patients with recalcitrant PV.
• The addition of systemic tacrolimus allowed for a reduction in corticosteroid dosage.
• Tacrolimus demonstrated efficacy in managing severe oral pemphigus vulgaris symptoms.

Implications:

• Systemic tacrolimus may represent a viable therapeutic alternative for patients with recalcitrant pemphigus vulgaris.
• Further research is warranted to confirm the safety and efficacy of tacrolimus in a larger PV patient cohort.
• This finding could lead to improved treatment strategies for autoimmune blistering skin diseases.